BRUSSELS — 18 June 2026 | In a landmark gathering at the European Parliament, a coalition of leading respiratory experts, healthcare advocates, and policymakers has issued an urgent call to action regarding the upcoming overhaul of the European Union’s Tobacco Products Directive (TPD) and Tobacco Advertising Directive (TAD). As the European Commission prepares to finalize its legislative revisions by the end of 2026, stakeholders are framing the moment as a “last-chance” window to curb a rapidly evolving nicotine epidemic that threatens the health of the next generation.
The event, titled “Say No to Nicotine,” was organized by a prominent alliance of health advocates—including the European Respiratory Society (ERS)—and hosted by Members of the European Parliament (MEPs) Aurelijus Veryga and Romana Jerković, with critical support from MEP Tilly Metz. The consensus among the speakers was stark: the current regulatory framework is not merely outdated; it is being actively exploited by an industry that has mastered the art of bypassing existing health safeguards.
The Core Challenge: Keeping Pace with Industry Innovation
The central narrative emerging from the Brussels summit is the mismatch between the agility of the tobacco industry and the relative inertia of legislative bodies. For decades, tobacco control policy focused on traditional combustible cigarettes. However, the market has shifted dramatically. Today’s landscape is dominated by high-tech, highly engineered products—such as sleek e-cigarettes and high-potency nicotine pouches—designed specifically to maximize user appeal while masking the inherent dangers of nicotine.
Chronology of the Regulatory Landscape
- Pre-2024: EU regulation remained largely focused on traditional tobacco products, with early, fragmented attempts to categorize e-cigarettes.
- 2024–2025: A surge in the availability of high-dose nicotine pouches (reaching up to 15mg per unit) sparked alarms among pediatricians and cardiologists across the EU.
- June 2026: The “Say No to Nicotine” event at the European Parliament serves as a catalyst for advocacy, aiming to influence the drafting phase of the TPD and TAD revisions.
- Late 2026 (Projected): The European Commission is expected to table the official revision of the Tobacco Products and Advertising Directives, setting the stage for a new era of EU-wide regulation.
Supporting Data: The Anatomy of an Epidemic
The alarm bells ringing in Brussels are not based on conjecture but on rising clinical and demographic data. Dr. Angela Ciobanu of the World Health Organization (WHO) Europe presented a chilling assessment of how these products are engineered. According to her analysis, modern nicotine products are not merely “alternatives”; they are sophisticated delivery systems optimized for addiction.
Marketing and Design Tactics
Industry insiders have utilized aggressive pricing strategies, vibrant, youth-oriented packaging, and the introduction of enticing flavors to infiltrate markets previously untouched by traditional smoking.
Demographic Shifts
Perhaps the most harrowing statistic presented was the current state of consumption in Sweden. Despite being frequently cited by industry lobbyists as a “success story” for harm reduction, the data reveals a different reality: the 17- to 29-year-old demographic in Sweden now reports the highest nicotine usage rates globally. This directly contradicts the industry’s claim that these products are intended solely for older smokers looking to quit.
The Hidden Cardiovascular Toll
Cardiologists at the event issued a stern warning: the long-term impact of non-combustible nicotine products is often minimized by the public, but the biological reality is dire. Nicotine is a potent toxin that causes systemic damage to the vascular system long before overt cardiovascular events like heart attacks manifest. Medical experts estimate that the full, catastrophic scale of this "nicotine epidemic" will only become fully visible in 15 to 20 years, creating a future burden on healthcare systems that is currently being ignored.
Official Responses and Expert Testimony
The event provided a platform for high-level experts to dismantle the “harm reduction” narrative currently being pushed by industry lobbyists.
Dr. Filippos Filippidis, Chair of the ERS Tobacco Control Committee:
"Young people are being targeted by the powerful tobacco industry, which continues to promote its harmful and addictive tobacco and nicotine products. We are at a crucial time for public health in Europe, as many of the regulations will soon be updated. We need to ensure that EU Directives provide adequate protection to young generations. We know what works; implementing evidence-based policies can prevent nicotine addiction and millions of deaths."
MEP Aurelijus Veryga’s Precautionary Principle:
MEP Veryga advocated for a fundamental shift in how the EU handles new products. He argued that the burden of proof should rest on the manufacturer. Instead of the current reactive model—where regulators wait for evidence of harm before restricting a product—Veryga proposed a “precautionary approach.” Under this framework, companies would be required to provide rigorous proof of safety before a product is allowed on the market, particularly given the unknown long-term health effects of inhaling synthetic substances not originally intended for the human lungs.
Addressing Industry Interference
A significant portion of the discussion was dedicated to the opaque nature of tobacco industry lobbying. Speakers highlighted a sophisticated campaign of misinformation circulating within the European Parliament. This includes the manufacturing of "grassroots" support through anonymous citizen consultations and the use of "harm reduction" as a shield to block stricter taxation and advertising bans.
The consensus was clear: the industry’s claim that nicotine pouches are a public health solution is unsupported by clinical research. Medical professionals pointed out that if a patient truly wishes to cease nicotine consumption, there are already safe, medically approved nicotine replacement therapies (NRTs) available. The proliferation of commercial nicotine products, they argued, is a strategy for profit-seeking, not for public health.
Implications for the TPD and TAD Revision
The upcoming revisions of the TPD and TAD represent a pivotal moment for European sovereignty in public health. To be effective, experts argued, the new directives must address three primary failures in the current system:
- Fragmentation of Rules: Currently, national regulations across the EU are inconsistent, leading to cross-border evasion and "regulatory tourism," where products banned in one country are easily purchased in another.
- Taxation Loopholes: Taxation remains the most potent tool in controlling consumption, yet emerging products frequently enjoy favorable tax status compared to traditional cigarettes, keeping them affordable for younger demographics.
- Product Categorization: The current legal definitions are insufficient to capture the technical evolution of nicotine products. The new directives must ensure that all nicotine-containing products are subject to the same strict standards regarding flavorings, marketing restrictions, and disclosure of chemical composition.
A Call for Uniformity
The speakers concluded that the European Union must move toward a harmonized, stringent regulatory framework. By closing these loopholes, the EU has the potential to lead the global community in preventing a new generation from falling into the trap of lifelong nicotine dependence.
As the 2026 deadline approaches, the pressure is mounting on the European Commission to prioritize the health of its citizens over the commercial interests of the tobacco industry. The message from the Brussels event was unequivocal: history will judge this legislative session by whether it chose to protect the youth of Europe or bowed to the sophisticated, profit-driven narratives of the nicotine industry. The time for reactive policy is over; the era of proactive, science-led regulation must begin.
